These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1092 related items for PubMed ID: 9417395

  • 1. [Comparison of 6 different methods for lorazepam withdrawal. A controlled study, hydroxyzine versus placebo].
    Lemoine P, Touchon J, Billardon M.
    Encephale; 1997; 23(4):290-9. PubMed ID: 9417395
    [Abstract] [Full Text] [Related]

  • 2. A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective multicenter trial.
    Cutler NR, Sramek JJ, Keppel Hesselink JM, Krol A, Roeschen J, Rickels K, Schweizer E.
    J Clin Psychopharmacol; 1993 Dec; 13(6):429-37. PubMed ID: 7907097
    [Abstract] [Full Text] [Related]

  • 3. [alpha-beta L-aspartate magnesium in treatment of chronic benzodiazepine abuse: controlled and double-blind study versus placebo].
    Hantouche EG, Guelfi JD, Comet D.
    Encephale; 1998 Dec; 24(5):469-79. PubMed ID: 9850822
    [Abstract] [Full Text] [Related]

  • 4. Double-blind, placebo-controlled trial of two doses of abecarnil for geriatric anxiety.
    Small GW, Bystritsky A.
    J Clin Psychiatry; 1997 Dec; 58 Suppl 11():24-9. PubMed ID: 9363045
    [Abstract] [Full Text] [Related]

  • 5. [Modification of cognitive functions by 2 anxiolytic treatments in patients suffering from generalized anxiety].
    Samuelian JC, Billardon M, Guillou N.
    Encephale; 1995 Dec; 21(2):147-53. PubMed ID: 7781586
    [Abstract] [Full Text] [Related]

  • 6. [Value of hydroxyzine in generalized anxiety disorder: controlled double-blind study versus placebo].
    Ferreri M, Hantouche EG, Billardon M.
    Encephale; 1994 Dec; 20(6):785-91. PubMed ID: 7875114
    [Abstract] [Full Text] [Related]

  • 7. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
    Naukkarinen H, Raassina R, Penttinen J, Ahokas A, Jokinen R, Koponen H, Lepola U, Kanerva H, Lehtonen L, Pohjalainen T, Partanen A, Mäki-Ikola O, Rouru J, Deramciclane Dose-Finding Study Group.
    Eur Neuropsychopharmacol; 2005 Dec; 15(6):617-23. PubMed ID: 15949921
    [Abstract] [Full Text] [Related]

  • 8. Safety of ipsapirone treatment compared with lorazepam: discontinuation effects.
    Busto UE, Naranjo CA, Bremner KE, Peachey JE, Bologa M.
    J Psychiatry Neurosci; 1998 Jan; 23(1):35-44. PubMed ID: 9505058
    [Abstract] [Full Text] [Related]

  • 9. [A controlled double-blind study of tetrabamate versus lorazepam and placebo in generalized anxiety].
    Lôo H, Malka R, Hantouche E, Lancrenon S, Guelfi JD.
    Encephale; 1991 Jan; 17(4):295-300. PubMed ID: 1959498
    [Abstract] [Full Text] [Related]

  • 10. [Treatment of generalized anxiety: new pharmacologic approaches].
    Boulenger JP.
    Encephale; 1995 Jan; 21(6):459-66. PubMed ID: 8674471
    [Abstract] [Full Text] [Related]

  • 11. Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone.
    Pollack MH, Worthington JJ, Manfro GG, Otto MW, Zucker BG.
    J Clin Psychiatry; 1997 Jan; 58 Suppl 11():19-23. PubMed ID: 9363044
    [Abstract] [Full Text] [Related]

  • 12. [Efficacy and withdrawal of clobazam, lorazepam and buspirone in the treatment of anxiety disorders].
    Lemoine P, Rouillon F, Pouget D.
    Encephale; 1996 Jan; 22(6):461-7. PubMed ID: 10901839
    [Abstract] [Full Text] [Related]

  • 13. A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. Abecarnil Work Group.
    Lydiard RB, Ballenger JC, Rickels K.
    J Clin Psychiatry; 1997 Jan; 58 Suppl 11():11-8. PubMed ID: 9363043
    [Abstract] [Full Text] [Related]

  • 14. The safety and efficacy of ipsapirone vs. lorazepam in outpatients with generalized anxiety disorder (GAD): single site findings from a multicenter trial.
    Cutler NR, Sramek JJ, Wardle TS, Hesselink JM, Roeschen JK.
    Psychopharmacol Bull; 1993 Jan; 29(2):303-8. PubMed ID: 7904761
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice.
    Nguyen N, Fakra E, Pradel V, Jouve E, Alquier C, Le Guern ME, Micallef J, Blin O.
    Hum Psychopharmacol; 2006 Apr; 21(3):139-49. PubMed ID: 16625522
    [Abstract] [Full Text] [Related]

  • 16. Comparative studies on the effects of the combination drug lorazepam plus diphenhydramine (Somnium) versus lorazepam on the noopsyche, thymopsyche and psychophysiology in nonorganic insomnia related to generalized anxiety disorder.
    Grünberger J, Saletu B, Linzmayer L, Böck G, Weissgram S, Brandstaätter N, Frey R, Saletu-Zyhlarz G.
    Methods Find Exp Clin Pharmacol; 1997 Nov; 19(9):645-54. PubMed ID: 9500129
    [Abstract] [Full Text] [Related]

  • 17. Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized, placebo-controlled study.
    Gerra G, Zaimovic A, Giusti F, Moi G, Brewer C.
    Addict Biol; 2002 Oct; 7(4):385-95. PubMed ID: 14578014
    [Abstract] [Full Text] [Related]

  • 18. [Antiparkinson drugs in neuroleptic treatment: comparative study of progressive and abrupt withdrawal].
    Ben Hadj Ali B, Dogui M, Ben Ammou S, Lôo H.
    Encephale; 1995 Oct; 21(3):209-15. PubMed ID: 7649071
    [Abstract] [Full Text] [Related]

  • 19. The role of captodiamine in the withdrawal from long-term benzodiazepine treatment.
    Mercier-Guyon C, Chabannes JP, Saviuc P.
    Curr Med Res Opin; 2004 Sep; 20(9):1347-55. PubMed ID: 15383182
    [Abstract] [Full Text] [Related]

  • 20. Low-sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients: a double-blind study.
    Cohn JB, Wilcox CS.
    J Clin Psychiatry; 1986 Aug; 47(8):409-12. PubMed ID: 2874128
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.